Table 1 Demographic characteristics of the patients
Characteristic | |
|---|---|
Age - median in years (range) | 40.5 (16-56) |
Sex - male/female | 17/13 |
Underlying disease - n (%) | |
Malignant disease | |
Acute lymphocytic leukemia (ALL) | 4 (13.3%) |
Acute myelogenous leukemia (AML) | 10 (33.3%) |
Chronic lymphocytic leukemia (CLL) | 1 (3.3%) |
Chronic myelogenous leukemia (CML) | 4 (13.3%) |
Non-Hodgkin's lymphoma (NHD) | 2 (6.7%) |
Hodgkin's disease (HD) | 3 (10%) |
Multiple myeloma (MM) | 1 (3.3%) |
Myelofibrosis | 2 (6.7%) |
Non-malignant disease | |
Severe aplastic anaemia (SAA) | 3 (10%) |
Acute GVHD - (n%) | 11 (36.7%) |
Pretransplant CMV sorostatus - (n%) | |
D+/R+ | 30 (100%) |
Conditioning regimen - (n%) | |
Myeloablative transplant | |
BU + FLU | 7 (23.3%) |
BU + Cy | 6 (20%) |
BU+ Cy + VP-16 | 3 (10%) |
Cy + VP-16 + TBI | 2 (6.7%) |
Cy + TBI | 1 (3.3%) |
Non-myeloablative transplant | |
FLU + TBI | 9 (30%) |
FLU + TBI + ARA-C | 1 (3.3%) |
GVHD prophylaxis - (n%) | |
CsP | 2 (6.7%) |
CsP + MMF | 7 (23.3%) |
CsP + MTX | 20 (66.7%) |
CsP + MTX + Mitoxantrone + Cy | 1 (3.4%) |
Stem cell source | |
Bone marrow | 15 (50%) |
Peripheral blood | 15 (50%) |
Deaths | 13 (43.3%) |